Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
2.490
-0.010 (-0.40%)
At close: Oct 8, 2025, 4:00 PM EDT
2.590
+0.100 (4.02%)
After-hours: Oct 8, 2025, 7:59 PM EDT
Traws Pharma Employees
As of December 31, 2024, Traws Pharma had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees decreased by 11 or -61.11% compared to the previous year.
Employees
7
Change (1Y)
-11
Growth (1Y)
-61.11%
Revenue / Employee
$414,714
Profits / Employee
-$728,286
Market Cap
17.59M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | -11 | -61.11% |
| Dec 31, 2023 | 18 | 1 | 5.88% |
| Dec 31, 2022 | 17 | 2 | 13.33% |
| Dec 31, 2021 | 15 | 3 | 25.00% |
| Dec 31, 2020 | 12 | -7 | -36.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TRAW News
- 7 weeks ago - Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - GlobeNewsWire
- 7 weeks ago - Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - GlobeNewsWire
- 2 months ago - Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewsWire
- 3 months ago - Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions - GlobeNewsWire
- 4 months ago - Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib - GlobeNewsWire
- 4 months ago - Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness - GlobeNewsWire
- 5 months ago - Traws Pharma Reports First Quarter 2025 Results and Business Highlights - GlobeNewsWire